1-Panel Urine Test:
|1 to 24||$1.99|
|25 to 99||$1.75|
|100 and up||$1.49|
- In Stock -
Specificity - MTD Drug Test Panel
The following compounds are detected positive in urine by the MTD One Step Methadone Drug Test at 5 minutes. Cutoff represents the concentration of each compound required to yield a positive reading. A lower cutoff indicates a greater ability to detect the compound.
|Compound||Synonyms / Brand Names / Common Names||Cutoff
|Methadone||Methadon, Metadone, Metadona / Dolophine, Methadone Hydrochloride Intensol, Methadose / Dones||300|
|Doxylamine||Doxylamin, Doxilamina / Bonjesta, Diclegis, NyQuil, Unisom||50,000|
Summary - MTD Drug Test Panel
Methadone is a synthetic opioid, with the properties of a full opioid agonist. As an analgesic, methadone can be prescribed for treating pain; though it is best known for treating opioid use disorder (OUD). During medication-assisted therapy (MAT), the use of shorter acting and highly addictive opioids, such as heroin or oxycodone, is replaced with controlled and medically-supervised dosing of a longer acting, less addictive, and less euphoric opioid, typically buprenorphine or methadone.  This approach allows the opioid-addicted patient to avoid the persistent cravings and roller-coaster effects associated with short-acting opioid use, in addition to the debilitating withdrawal symptoms associated with cold-turkey abstinence. MAT allows for the patient to reach a level of stability, where patient and clinician may choose to continue with opioid maintenance treatment or pursue withdrawal management.   With any approach to treating opioid use disorder, concurrent psychosocial treatment is viewed as an essential cornerstone. 
Under US federal law, methadone patients for opioid use disorder (OUD) cannot be provided with monthly or weekly take-home prescriptions. Instead, certified opioid treatment programs (OTPs) must provide daily supervised dosing of methadone to their patients. OUD patients are allowed take-home methadone doses only under very limited circumstances.  These restraints do not apply to methadone prescribed for treating pain. Consequently, diverted pain prescriptions are a major source of illicit street methadone.  While physicians are discouraged from prescribing methadone as a first option for treating most types of pain,  many view methadone as a valuable option for treating cancer-related pain. 
Methadone is commonly found in oral tablet and liquid forms. For those physically dependent on opioids, methadone produces minimal levels of euphoria, yet is effective at curbing cravings and withdrawal symptoms — the primary motive for most illicit use of methadone.  For those with no physical dependence (opioid naive), methadone produces significantly stronger effects. Methadone has a very long duration of action and a long and unpredictable half-life.  Additionally, methadone can accumulate in the liver, then slowly release into the bloodstream over time.  These factors lead to a great deal of uncertainty with dosing and a high risk for respiratory depression and overdose, especially in new, opioid naive users and those taking benzodiazepines, such as Xanax.  In 2009, methadone was involved in 30% of opioid overdose deaths, while accounting for only 2% of opioid prescriptions. The majority of overdoses are believed to involve illicit methadone obtained through diverted pain prescriptions. Accordingly, the FDA and DEA have made efforts to reduce pain prescriptions for methadone, with some success. 
Methadone is the target compound for the MTD One Step Methadone Drug Test, detected at a cutoff level of 300 ng/mL. Methadone products are indicated either for treating opioid addiction/dependence only or for treating pain in addition to opioid addiction/dependence. Methadone products indicated for treating opioid addiction/dependence only are dispensed: in dispersible tablet form under generic labels and the brand Methadose; in oral concentrate form under generic labels and the brand Methadose;  and in oral powder form (for compounding) under generic labels. Methadone products indicated for treating opioid addiction/dependence in addition to pain are dispensed: in oral tablet form under generic labels and the brand Dolophine;  in oral solution form under generic labels; in oral concentrate form under the brand Methadone Hydrochloride Intensol; and in injectable form under generic labels. Following methadone use, approximately 5–50% is excreted in the urine as unchanged methadone, 2–25% as EDDP, and less than 1% as EMDP. These rates are significantly impacted by variations in urine pH, urine volume, dose, and rate of metabolism.